-

Axion BioSystems Welcomes Industry Leader David Ferrick as New CSO

ATLANTA--(BUSINESS WIRE)--Axion BioSystems, a leading life science tools company, has announced the appointment of David Ferrick as Chief Scientific Officer. Dr. Ferrick joins Axion with over 20 years of experience commercializing life science products into new and emerging markets.

“David’s extensive knowledge of the immunology and cancer fields, combined with his experience leading innovative new tools, makes him the ideal choice to champion the Maestro platform,” said Tom O’Brien, CEO of Axion BioSystems. “As we continue to expand our position in the immuno-oncology market, his expertise will be invaluable and I’m excited to see where David takes us.”

Dr. Ferrick joins Axion BioSystems from Agilent Technologies, where he led New Market Development and Strategy for the Cell Analysis Division. Prior to that, he was CSO for Seahorse Bioscience and has held senior positions in several biotech companies. He has led commercialization efforts for many nascent life science products, including diagnostics and drug-screening programs from target identification to preclinical testing.

Dr. Ferrick began his career as a University of California professor-turned-entrepreneur and is currently a life sciences industry executive focused on drug discovery and diagnostics in the areas of immunology and cancer. He has authored over 150 peer-reviewed publications, is an inventor on 20 patents, and has contributed to numerous high profile trade articles and interviews. Dr. Ferrick received his Ph.D. in Microbiology and Immunology from Georgetown University in Washington D.C.

“Axion’s innovative bioelectronic solutions have changed the way scientists approach the study of neurological disease and I see the same potential for emerging areas such as immuno-oncology and immune-based medicines, which have by need become very cell centric. I’m looking forward to continuing to build on their momentum and growth as I take on this new role,” says Dr. Ferrick.

About Axion BioSystems

Axion BioSystems is a leading life science tools company focused on developing and commercializing label-free, bioelectronic assays used to study the function of live cells in vitro for drug discovery and disease modeling. The team at Axion BioSystems is dedicated to continuing the advancement of bioelectronic assay technology that enables the understanding of biological complexity outside of the body. Axion BioSystems is headquartered in Atlanta, Georgia, USA, and also has an office in Shanghai, China. Axion has more than 60 employees across its current locations. www.axionbiosystems.com

Contacts

Mike Clements
678-469-3439
mclements@axionbio.com

Axion BioSystems


Release Summary
Axion BioSystems welcomes David Ferrick as new Chief Scientific Officer (CSO).
Release Versions

Contacts

Mike Clements
678-469-3439
mclements@axionbio.com

Social Media Profiles
More News From Axion BioSystems

Harnessing Combined Expertise: STEMCELL Technologies and Axion BioSystems Partner to Streamline Culture and Analysis of Excitable Cells

ATLANTA & VANCOUVER, British Columbia--(BUSINESS WIRE)--Axion BioSystems and STEMCELL Technologies are pleased to announce a strategic partnership that will enable STEMCELL to sell Axion’s state-of-the-art Maestro Pro™ and Maestro Edge™ multielectrode array (MEA) systems within North America and Europe. The industry-leading Maestro MEA systems will also continue to be available for purchase worldwide directly from Axion BioSystems. Through this partnership, Axion and STEMCELL will enable scient...

Axion BioSystems Continues Agreement Giving Corning® Exclusive Rights to Distribute Award-Winning Cell Counting Device

ATLANTA--(BUSINESS WIRE)--Axion BioSystems today announced an agreement with Corning Incorporated (NYSE: GLW) that continues Corning’s exclusive worldwide distribution rights for the Corning® Cell Counter. The simple yet powerful device, developed by Axion BioSystems and distributed by Corning, was recently included in the SelectScience® top 10 list of remarkable products advancing life science research. The agreement extends the successful collaboration between Corning and Axion BioSystems to...

Axion BioSystems Adds Affordable Maestro Volt™ to its Industry-Leading MEA System Lineup

ATLANTA--(BUSINESS WIRE)--Axion BioSystems today announced the launch of the new Maestro Volt™, an affordable benchtop microelectrode array (MEA) system designed to meet the demands of academic labs with lower throughput needs and limited budgets. Featuring the same ease of use, high-quality controls, and intuitive software synonymous with the Maestro name, the 6-well Maestro Volt is available for both neurological and cardiovascular research applications. The new device expands Axion’s flagshi...
Back to Newsroom